Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Large cohort study: Bevacizumab safe, effective for severe HHT bleeds

Publish date:: July 29, 2020

Key clinical point: Bevacizumab is safe and highly effective for HHT bleeding.

Major finding: Mean hemoglobin increased by 3.2 g/dL, ESS decreased by a mean of 3.4 points, red blood cell units transfused decreased by 82%

Study details: An international observational cohort study of 238 patients

Disclosures: Dr. Al-Samkari reported receiving research support and/or consulting fees from Agios, Dova, and Amgen.

Citation:

Al-Samkari H et al. ISTH 2020. Abstract OC 09.2.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Hematology

Emotions, worse attention linked to pain-related health care use SCD,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Large cohort study: Bevacizumab safe, effective for severe HHT bleeds,

SPK-8011 AAV-mediated Hemophilia A therapy shows stability, durability,

Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders,

All Specialties